PNC-27 Kills Cervical Cancer Cells but Not Untransformed Cervical Cells, an Effect that is Enhanced by Ketone Bodies.

Main Article Content

Anna I. Miller Lucas Miller Shabnam Seydafkan Steven Mc Glinchey Gholamali Jafari Miriam Silberstein Patryck Krzesaj Richard D. Feinman Matthew R. Pincus

Abstract

The anti-cancer peptide, PNC-27, is cytotoxic to cancer cells but has no effect on normal cells and has eradicated tumors in vivo with no off-target effects. We have recently treated three different cervical cancer cell lines with this peptide including two squamous cervical cancers (HTB-35 and SW756) and one endo-cervical cancer (HeLa) and found that it killed all three cell lines with IC50 values among the lowest values that we have found for a wide variety of cancers. On the other hand, PNC-27 had no effect on the viability or growth of PCS-480-011 primary normal cervical epithelial cells. We have recently found that lithium acetoacetate inhibits the proliferation of cancer but not normal cells without exhibiting any cytotoxicity. When administered to cancer cells with chemotherapeutic compounds, this agent causes significant lowering of the IC50 values for the chemotherapeutic compounds. We now find that lithium acetoacetate induces a lowering of the IC50 values of PNC-27 on all three cervical cancer cell lines by 200-300 percent. These results suggest that PNC-27 in acetoacetate solutions can be a powerful antitumor agent.

Keywords: PNC-27, cervical cancer, ketone bodies, IC50 values, dose-response curves

Article Details

How to Cite
MILLER, Anna I. et al. PNC-27 Kills Cervical Cancer Cells but Not Untransformed Cervical Cells, an Effect that is Enhanced by Ketone Bodies.. Medical Research Archives, [S.l.], v. 13, n. 5, may 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6471>. Date accessed: 21 june 2025. doi: https://doi.org/10.18103/mra.v13i5.6471.
Section
Research Articles

References

.Sarafraz-Yazdi E, Bowne, WB, Adler, V, Sookraj KA, Wud V, Shteyler V,Patel H, Oxbury W, Brandt-Rauf W, Zenilman ME, Michl J, Pincus, MR. Anticancer Peptide PNC-27 Adopts an HDM-2-Binding Conformation and Kills Cancer Cells by Binding to HDM-2 in their Membranes. Proc Natl Acad Sci USA. 2010; 107:1918-1923.

2.Sarafraz-Yazdi E, Mumin S, Cheung D, Fridman D, Lin B,Wong L, Rosal R, Rudolph R, Frenkel M, Thadi A, Morano WF, Bowne WB, Pincus MR, Michl JP. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022;10: 945. https://doi.org/10.3390/biomedicines10050945.

3.Pincus MR, Bowne WB, Sarafraz-Yazdi, E. Poptosis: A Novel Mechanism for the
Selective Killing of Cancer Cells. Clin Oncol. 2023; 7 (6): 1-13 , ISSN: 2640-1037.

4.Pincus MR, Silberstein M, Zohar N, Sarafraz-Yazdi E, Bowne WB. Poptosis or Peptide-Induced Transmembrane Pore Formation: A NovelWay to Kill Cancer Cells without Affecting Normal Cells. Biomedicines. 2024;12: 1144. https://doi.org/10.3390/biomedicines12061144.

5. Michl J, Scharf B, Schmidt A, Hannan R, von Gizycki H, Friedman FK, Brandt-Rauf PW, Fine RL, Pincus MR. PNC-28, a p53 Peptide that Is Cytotoxic To Cancer Cells, Blocks Pancreatic Cancer Cell Growth in vivo. Int J Cancer. 2006; 119, 1577-1585.

6. Wang H, Zhao D, Nyguyen LX, Wuz H, Ling L, Dong D, Troadec E, Zhu Y, Hoang DH, Stein AS, et al. Targeting Cell Membrane HDM2: A Novel Therapeutic Approach for Acute Myeloid Leukemia. Nat. Leuk. 2019; 34, 75–86.

7. Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, Rubinstein P, Visser I, Robinson R, Brandt-Rauf PW, Michl J, Fine RL, Pincus MR. Peptides from the Amino Terminal mdm-2 Binding Domain of p53, Designed from Conformational Analysis, Are Selectively Cytotoxic to Transformed Cells. Proc Natl Acad Sci USA. 2001;98, 12438-12443.

8.Miller A, Lin B, Pincus MR, Fine E and Feinman RD. Selective Enhancement of Chemotherapeutic Agent-Induced Tumor Cell Killing by Acetoacetate and 3-Hydroxybutyrate. EC Pharmacology and Toxicology 2021;9, 29-34.

9. Miller AI, Diaz D, Lin B, Krzesaj PK, Ustoyev S, Shim A, Fine EJ, Sarafraz-Yazdi E, Pincus
MR, Feinman RD, Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents. Biomedicines. 2023; 11, 2515.
https://doi.org/10.3390/biomedicines11092515.

10.Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate Reduces Growth and ATP Concentration in Cancer Cell Lines Which Over-Express Uncoupling Protein 2. Cancer Cell Int. 2009: 9, 14.

11. Warburg O. On the origin of cancer cells. Science. 1956;123: 309-314.

12. Zo Y, Fineberg S, Pearlman A, Feinman RD, Fine EJ. The Effect of a Ketogenic Diet and Synergy with Rapamycin in a Mouse Model of Breast Cancer. PLoS ONE. 2020:15, e0233662.

13. Schwartz E, Freese UK, Gissman L, Mayer W, Roggenbuck B, Stremlau A, Zur Hausen H. Structure and Transcription of Human Papillomavirus Sequences in Cervical Carcinoma Cells. Nature. 1985: 314, 111-114.

14.Macville M, Schrock E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonic D, Popescur N, Ried T. Comprehensive and Definitive Molecular Cytogenetic Characterization of HeLa Cells by Spectral Karyotyping. Cancer Res. 1999: 59 (1), 141–150.

15.Miekus K, Pawlowska M, Sekuła M, Drabik G, Madeja Z, Adamek D, Majka M. MET Receptor Is a Potential Therapeutic Target in High Grade Cervical Cancer. Oncotarget. 2015: Apr 30;6(12),10086-10101. doi: 10.18632/oncotarget.3161. PMID: 25888626; PMCID: PMC4496342